• Guiding Evidence-Based Therapy Using Biomarker-Intensified Treatment (GUIDE-IT):

    The primary objective of this study is to determine the efficacy of biomarker-guided therapy compared with usual care in high-risk patients with left ventricular systolic dysfunction.

  • American Heart Association Heart Failure Strategically-Focused Research Network:

    This multi-center research network will focus on the understanding, prevention, diagnosis, and treatment of heart failure. Intermountain Medical Center Heart Institute participates in collaboration with University of Utah Health Care.

  • Barostim Therapy for Heart Failure (BeAT-HF):

    This phase III clinical trial is designed to demonstrate the safety of Barostim neo, Baroreflex Activation Therapy System, and its effectiveness on symptoms and clinical outcomes in patients suffering from chronic heart failure.

  • Perhexiline Study:

    The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.